longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Ord Minnett Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Tip Ranks
Aug 24, 2026 at 02:06 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Ord Minnett reaffirmed its Buy rating on Telix Pharmaceuticals (TLPPF) with a price target of A$20.40. This follows a Buy recommendation from Jefferies’s David Stanton on August 21, while RBC Capital maintained a Hold rating on the stock on August 20.

In a report released today, from Ord Minnett maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$20.40.

Summer Sale - Claim 70% Off TipRanks

  • Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
  • Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

In addition to Ord Minnett, Telix Pharmaceuticals also received a Buy from Jefferies’s David Stanton in a report issued on August 21. However, on August 20, RBC Capital maintained a Hold rating on Telix Pharmaceuticals (Other OTC: TLPPF).

Login to unlock130characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 9, 2026 at 10:32 AMNvidia to Attend Goldman Sachs Tech Conference: What Investors Need to Watch
  • Sep 9, 2026 at 09:06 AMOracle Earnings Preview: RPO and Cash Flow in Focus, Wall Street Sees Up to $400

Related Stocks

Telix Pharmaceuticals

Telix Pharmaceuticals

USTLX

+0.34%

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd.

AUTLX

Jefferies Financial

Jefferies Financial

USJEF

LongbridgeAI